1. Ahearn MJ, Lewis CW, Campbell LA, Luce JK (1967) Nuclear bleb formation in human bone marrow cells during cytosine arabinoside therapy. Nature 215: 196–197
2. Aoshima M, Tsukagoshi S, Sakurai Y, Oh-ishi J, Ishida T, Kobayashi H (1977) N4-behenoy D-arabinofuranosylcytosine as a potential new antitumor agent. Cancer Res 37: 2481–2486
3. Bach MK (1969) Biochemical and genetic studies of a mutant strain of mouse leukemia L1210 resistant to 1D-arabinofuranosylcy tosine (Cytarabine) hydrochloride. Cancer Res 29: 1036–1044
4. Bader JP (1966) Metabolic requirements for infection by Rous sarcoma virus. I. The transient requirement for DNA synthesis. Virology 29: 444–451
5. Baguley BC, Falkenhaug EM (1971) Plasma half-life of cytosine arabinoside (NCS-63878) in patients treated for acute myeloblastic leukemia. Cancer Chemother Rep 55: 291–298